about
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyBRCA1 modulates the expression of hnRNPA2B1 and KHSRP.Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy.An improved sequencing-based strategy to estimate locus-specific DNA methylation.Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way.Mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres.BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1.Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers.A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness.Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer.BRCA1 andBRCA2 genes: Role in hereditary breast and ovarian cancer in ItalyDifferent Expressivity of BRCA1 and BRCA2: Analysis of 179 Italian Pedigrees with Identified MutationExpression and release of intercellular adhesion molecule-1 in renal-cancer patientsInterleukin-6 and soluble intercellular adhesion molecule-1 in renal cancer patients and cultured renal cancer cellsLow incidence of BRCA1 mutations among Italian families with breast and ovarian cancerPenetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutationsSplice variant lacking the transactivation domain of theBRCA2 gene and mutations in the splice acceptor site of intron 2Splice variant lacking the transactivation domain of the BRCA2 gene and mutations in the splice acceptor site of intron 2BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in ItalyCorrection to: A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness
P50
Q27860519-CE7EE2E0-D37A-480B-B704-309FB7A091FFQ30992379-896EA922-8CA2-41D9-AC30-C0A4F85E674FQ33246295-06010D1D-446E-41CC-8253-58435D01AC90Q35782282-FEC1BEFF-1FDD-4D48-9B2A-85222431A92EQ35789595-88678BD1-1343-4704-A3C8-B956545FFBB8Q36472268-1C9AEE03-B01D-44A4-B038-489D3FC55BC5Q37958686-3D6B08A8-3DB3-46F5-A999-8F04FAE6ABAEQ39311503-494D9A3E-8849-44E5-A0E7-7A10CD3D2FCBQ39860034-162520A5-59C7-4204-8359-7553423A64FDQ52318631-5769047F-D62E-4F1D-8237-7308284EEC94Q53942978-8BB45240-3E9F-4487-B321-A6D503DAD7FEQ57056340-8D279CF7-55F0-48BC-A830-EB37D476506DQ58813401-94AEEC02-4EE7-4E4C-B11E-B65496EA7674Q61561780-74F09B5F-C188-47C1-89EF-83A00BFBB4E2Q61561797-62A8A94B-1A57-4863-BAF8-F7C3007978BEQ61561804-14D97FA4-2FA0-4EFE-8482-C9CF136ADA24Q61561820-57EC728D-B2C2-4F2F-8FD6-D4A317C7EF8EQ61561832-CCDA9F23-9027-40D6-BE9D-9123298D49AAQ73115546-0AD5E878-5770-4E94-9F3D-761C12C0563DQ78132500-E4D95507-AC5F-44A5-9352-2D10AADFE8B1Q91387213-4CE586AB-ACA9-4BB0-95D3-DD7C53DDD858
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Manuela Santarosa
@ast
Manuela Santarosa
@en
Manuela Santarosa
@es
Manuela Santarosa
@nl
Manuela Santarosa
@sl
type
label
Manuela Santarosa
@ast
Manuela Santarosa
@en
Manuela Santarosa
@es
Manuela Santarosa
@nl
Manuela Santarosa
@sl
prefLabel
Manuela Santarosa
@ast
Manuela Santarosa
@en
Manuela Santarosa
@es
Manuela Santarosa
@nl
Manuela Santarosa
@sl
P106
P21
P31
P496
0000-0001-7682-2578